
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Avectas
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Inceptor will utilize Avectas' SOLUPORE® technology as an alternative to electroporation for engineering T cells with the goal to yield a healthier T cell product.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Avectas
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Kineticos Ventures
Deal Size : $37.0 million
Deal Type : Series A Financing
Inceptor Bio Announces $37 Million Series A Financing
Details : Proceeds from the Series A financing will be used to advance Inceptor Bio’s M83-based CAR-T Cell Therapy lead program to a Phase I clinical trial and continue development of its CAR-M and CAR-NK platforms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 19, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Kineticos Ventures
Deal Size : $37.0 million
Deal Type : Series A Financing
